Belite Bio (BLTE) EBITDA (2022 - 2026)

Belite Bio's EBITDA history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 88.79% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.3 billion (down 122.12% YoY), while the FY2025 annual figure was -$77.5 million, down 112.7% from the prior year.
• EBITDA was -$26.9 million for Q1 2026 at Belite Bio, up from -$25.4 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.7 million in Q4 2022 to a low of -$25.4 billion in Q4 2025.
• Historically, EBITDA has averaged -$7.4 billion across 5 years, with a median of -$6.9 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA slumped 150949.87% in 2024, then soared 99.82% in 2025.
• A 5-year view of EBITDA shows it stood at -$6.7 million in 2022, then retreated by 3.03% to -$6.9 million in 2023, then plunged by 150949.87% to -$10.4 billion in 2024, then slumped by 145.47% to -$25.4 billion in 2025, then surged by 99.89% to -$26.9 million in 2026.
• The last three EBITDA figures came in at -$26.9 million (Q1 2026), -$25.4 billion (Q4 2025), and -$21.6 billion (Q3 2025), per Business Quant data.